Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- H00001645-B01P - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#H00001645-B01P, RRID:AB_1214145
- Product name
- Mouse Polyclonal Aldo-keto Reductase 1C1/AKR1C1 Antibody
- Antibody type
- Polyclonal
- Description
- Protein A purified. AKR1C1 - aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 0.05 mg
- Storage
- Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Submitted references High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling.
NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells.
The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing.
An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells.
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Kim D, Choi BH, Ryoo IG, Kwak MK
Cell death & disease 2018 Aug 30;9(9):896
Cell death & disease 2018 Aug 30;9(9):896
NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells.
Choi BH, Ryu DY, Ryoo IG, Kwak MK
Oncotarget 2017 Dec 5;8(63):107188-107205
Oncotarget 2017 Dec 5;8(63):107188-107205
The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing.
Choi BH, Ryoo IG, Kang HC, Kwak MK
PloS one 2014;9(9):e107158
PloS one 2014;9(9):e107158
An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells.
Han H, Bourboulia D, Jensen-Taubman S, Isaac B, Wei B, Stetler-Stevenson WG
Oncogene 2014 Feb 27;33(9):1198-206
Oncogene 2014 Feb 27;33(9):1198-206
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B, Kisiela M, Wsól V, Maser E
Chemico-biological interactions 2011 May 30;191(1-3):239-49
Chemico-biological interactions 2011 May 30;191(1-3):239-49
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Aldo-keto Reductase 1C1/AKR1C1 Antibody [H00001645-B01P] - Analysis of AKR1C1 expression in transfected 293T cell line by AKR1C1 polyclonal antibody. Lane 1: AKR1C1 transfected lysate(35.53 KDa). Lane 2: Non-transfected lysate.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Aldo-keto Reductase 1C1/AKR1C1 Antibody [H00001645-B01P] - Analysis of AKR1C1 expression in human liver.
